|Bid||77.01 x 1000|
|Ask||77.03 x 800|
|Day's Range||76.41 - 77.66|
|52 Week Range||48.22 - 81.91|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||85.76|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Nuvasive saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 93 to 96. The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ): AbbVie Inc ...
Shares of medical device maker NuVasive, Inc. (NASDAQ: NUVA ) represent a particularly compelling opportunity, according to SunTrust Robinson Humphrey. The NuVasive Analyst Kaila Krum initiated coverage ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.